Problem: Mass spectrometry (MS) has become an indispensible technology for the analysis of compounds of biological interest, is widely available and offers rapid and accurate detection with broad applicability.

As more therapeutic proteins enter the market, an even larger number accumulate in biopharmaceutical drug pipelines. In order to improve assay quality and manage the growing workload, automated systems are needed to provide qualitative and quantitative information.